Related Experiment Video

Updated: May 23, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
07:08

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on: February 2, 2024

Adrenocortical carcinoma: past, present, and future

Jennifer Lafemina1, Murray F Brennan

  • 1Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Journal of Surgical Oncology
|April 5, 2012
PubMed

Insights

Adrenocortical carcinoma (ACC) is a rare endocrine cancer. This review examines current understanding and treatment strategies for ACC, highlighting the need for further research to improve patient outcomes.

Area of Science:

  • Endocrinology
  • Oncology
  • Cancer Research

Background:

  • Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis.
  • Limited understanding of ACC pathogenesis contributes to treatment challenges.
  • Heterogeneity of ACC complicates therapeutic approaches.

Purpose of the Study:

  • To review the historical context of adrenocortical carcinoma research.
  • To summarize the current state of knowledge regarding ACC pathogenesis and treatment.
  • To explore future directions for improving understanding and outcomes in ACC.

Main Methods:

  • Literature review of past, present, and future research on adrenocortical carcinoma.
  • Analysis of existing data on ACC epidemiology, molecular mechanisms, and clinical management.
  • Synthesis of information to identify research gaps and therapeutic opportunities.

Main Results:

  • ACC remains a challenging malignancy due to its rarity and complexity.
  • Progress in understanding ACC pathogenesis has been slow but is accelerating.
  • Current treatment options for ACC have limited efficacy.

Conclusions:

  • A comprehensive understanding of ACC pathogenesis is crucial for developing effective therapies.
  • Future research should focus on targeted therapies and personalized medicine approaches for ACC.
  • Improved diagnostic and therapeutic strategies are needed to enhance patient survival and quality of life for adrenocortical carcinoma.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...